Myriad Genetics (MYGN) Tops Q4 EPS by 6c, Offers Guidance
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $3.20 -0.62%
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.04, $0.06 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $209.8 million versus the consensus estimate of $207.17 million.
GUIDANCE:
Myriad Genetics sees Q1 2026 revenue of $200-203 million, versus the consensus of $211.3 million.
Myriad Genetics sees FY2026 revenue of $860-880 million, versus the consensus of $869.5 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA maintains underperform ratings on six BDC stocks
- Is the global equity rally broadening? UBS weighs in
- Kimbell Royalty closes $221.2M mineral rights acquisition
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
